# Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole

> **NCT00132496** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 111 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** rabeprazole sodium

## Key facts

- **NCT ID:** NCT00132496
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2006-05
- **Final completion:** 2006-07
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2009-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00132496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00132496, "Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00132496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*